<DOC>
	<DOCNO>NCT00563615</DOCNO>
	<brief_summary>Functional constipation common problem Hong Kong . In recent telephone survey , prevalence constipation define Rome II criteria 14 % . Apart organic , metabolic , neurological drug induce cause , constipation often arise 2 disorder colorectal motility : slow transit constipation pelvic floor dysfunction . In position statement American Gastroenterological Association , colon transit study recommend differentiate slow transit constipation pelvic floor dysfunction . The management algorithm normal transit slow transit constipation different surgery consider patient slow transit constipation . In recent paper Bonapace , scintigraphy could use study gastric , small bowel large bowel transit time . The clinical diagnosis change 51 % case constipation scintigraphy patient management add prokinetic agent , referral biofeedback center , decision surgery affect 64 % case . Tegaserod recently approve prokinetic agent market Hong Kong management patient constipation predominant irritable bowel syndrome ( C-IBS ) . In paper Mayo clinic base scintigraphic examination , tegaserod 2mg bd accelerate orocaecal transit C-IBS patient . However study functional constipation base tegaserod 6 mg twice daily publish yet . Therefore , Gastroenterology team nuclear medicine team Princess Margaret Hospital , Gastroenterology team Caritas Medical Center Yan Chai Hospital decide study small large bowel transit functional constipation patient scintigraphy . The efficacy tegaserod improve bowel transit also examine randomize double blind placebo control study .</brief_summary>
	<brief_title>Study Effect Tegaserod Small Large Bowel Transit Scintigraphic Method</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>History functional constipation propose Rome II Criteria usual frequency spontaneous bowel motion must equal less 2 time /week . An endoscopic/radiologic bowel evaluation ( colonoscopic examination and/or sigmoidoscopy + barium enema ) require patient old 40 year . This evaluation must perform within past 5 year . In addition , history evidence weight loss , anemia rectal bleeding since evaluation perform . Note : For patient require procedure , test perform patient sign informed consent least 7 day PRIOR start diary ( washout period ) . The 7day window allow patient recuperate prior collect baseline data . A copy report place patient source document . Patients able communicate well investigator comply requirement entire study , include withdrawal period . Patients provide write informed consent participate study give full description study . Medications know affect gastrointestinal transit 1 week treatment phase study . With clinical evidence ( include physical exam , vital sign , ECG , laboratory test ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematology , endocrine metabolic disorder , neurologic disease , disease may interfere patient successfully complete study . Existence surgical medical condition interfere absorption , distribution , metabolism excretion study medication . With hypo hyper thyroidism ( clinically significant abnormal TSH level screen ) . With symptom significant clinical illness two week precede baseline . With relevant intercurrent medical condition may interfere objective study . Women pregnant breastfeeding . With evidence history drug alcohol abuse within past 12 month . Who receive another investigational drug within 30 day prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Constipation ( idiopathic )</keyword>
</DOC>